期刊
ACTA NEUROPATHOLOGICA
卷 139, 期 1, 页码 3-25出版社
SPRINGER
DOI: 10.1007/s00401-019-02087-9
关键词
Immunotherapy; Alzheimer's disease; Seeding; Progressive supranuclear palsy; Secretion; CSF; Plasma; Tau
资金
- UCB Biopharma SPRL
- program Investissement d'avenir LabEx (laboratory excellence) DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to Alzheimer's disease)
- ANR grant GRAND
- ANR grant SPREADTAU
- ANR grant TONIC [ANR-14-CE13-0031]
- LiCEND (Lille Centre of Excellence in Neurodegenerative Disorders)
- CNRS
- Inserm
- Metropole Europeenne de Lille
- Univ. Lille
- FEDER
- DN2M
- Agence Nationale de la Recherche (ANR) [ANR-14-CE13-0031] Funding Source: Agence Nationale de la Recherche (ANR)
The term propagon is used to define proteins that may transmit misfolding in vitro, in tissues or in organisms. Among propagons, misfolded tau is thought to be involved in the pathogenic mechanisms of various tauopathies that include Alzheimer's disease, progressive supranuclear palsy, and argyrophilic grain disease. Here, we review the available data in the literature and point out how the prion-like tau propagation has been extended from Alzheimer's disease to tauopathies. First, in Alzheimer's disease, the progression of tau aggregation follows stereotypical anatomical stages which may be considered as spreading. The mechanisms of the propagation are now subject to intensive and controversial research. It has been shown that tau may be secreted in the interstitial fluid in an active manner as reflected by high and constant concentration of extracellular tau during Alzheimer's pathology. Animal and cell models have been devised to mimic tau seeding and propagation, and despite their limitations, they have further supported to the prion-like propagation hypothesis. Finally, such new ways of thinking have led to different therapeutic strategies in anti-tau immunotherapy among tauopathies and have stimulated new clinical trials. However, it appears that the prion-like propagation hypothesis mainly relies on data obtained in Alzheimer's disease. From this review, it appears that further studies are needed (1) to characterize extracellular tau species, (2) to find the right pathological tau species to target, (3) to follow in vivo tau pathology by brain imaging and biomarkers and (4) to interpret current clinical trial results aimed at reducing the progression of these pathologies. Such inputs will be essential to have a comprehensive view of these promising therapeutic strategies in tauopathies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据